Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

In Partnership With:

Partner | Cancer Centers | <b>Mayo Clinic</b>

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.